Ethical and design issues of Phase I clinical trials in cancer patients

Cancer Investigation

Volumn 25, Issue 2, 2007, Pages 124-126

  Grünwald, Hans W ^a,b,c  

^a QUEENS HOSPITAL CENTER   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c NONE   (United States)

Author keywords

Biomedical Ethics; Cancer Therapy; Phase I Clinical Trials

Indexed keywords

ALTRUISM; ARTICLE; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER THERAPY; HOSPICE CARE; HUMAN; INTERPERSONAL COMMUNICATION; METHODOLOGY; MOTIVATION; PATIENT INFORMATION; PATIENT SAFETY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RESEARCH ETHICS; RESEARCH SUBJECT; WELLBEING;

CLINICAL TRIALS, PHASE I; HUMANS; NEOPLASMS; RESEARCH DESIGN; TRUTH DISCLOSURE;

EID: 34247129602     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900701225331     Document Type: Article

References (31)

1. Sackett, D.L.; Rosenberg, W.M.C.; Gray, J.A.M.; Haynes, R.B.; Richardson, W.S. Evidence based medicine: what it is and what it isn't. BMJ 1995, 312, 71-72.
2. Sackett, DL. Evidence-Based Medicine; Howto Practice and Teach EBM. Churchill Livingstone; Edinburgh; 2000; 2nd ed.
3. Bates, B.R.; Harris, T.M. The Tuskegee Study of Untreated Syphilis and public perceptions of biomedical research: a focus group study. J. Natl. Med.Assoc. 2004, 96 (8), 1051-1064.
4. Stolberg, S.G. The biotech death of Jesse Gelsinger. NY Times Magazine 1999 Nov 28,136-140, 149-150.
5. Edwards, S.J.; Kirchin, S.; Huxtable, R. Research ethics committees and paternalism. J. Med. Ethics 2004, 30 (1), 88-91.
6. Storer, B.E. Design and analysis of phase I clinical trials. Biometrics 1989, 45 (3), 925-937.
7. Chevret, S. The continual reassessment method in cancer phase I clinical trials: a simulation study. Stat. Med. 1993, 12 (12), 1093-1108.
8. Gordon, N.H.; Willson, J.K. Using toxicity grades in the design and analysis of cancer phase I clinical trials. Stat Med. 1992, 11(16), 2063-2075.
9. Degos, L. Phase I trials in cancer treatment. The maximum tolerated dose: a barbarian guideline. Hematol. J. 2000, 1 (4), 219.
10. Korn, E.L.; Midthune, D.; Chen, T.T.; Rubinstein, L.V.; Christian, M.C.; Simon, R.M. A comparison of two phase I trial designs. Stat. Med. 1994, 13 (18), 1799-1806.
11. Goodman, S.N.; Zahurak, M.L.; Piantadosi, S. Some practical improvements in the continual reassessment method for phase I studies. Stat. Med. 1995, 14 (11), 1149-1161.
12. Babb, J.; Rogatko, A.; Zacks, S. Cancer phase I clinical trials: efficient dose escalation with overdose control. Stat. Med. 1998, 17 (10), 1103-1120.
13. Simon, R.; Freidlin, B.; Rubinstein, L.; Arbuck, S.G.; Collins, J.; Christian, M.C. Accelerated titration designs for phase I clinical trials in oncology. J. Natl. Cancer. Inst. 1997, 89 (15), 1138-1147.
14. Ivanova, A.; Montazer-Haghighi, A.; Mohanty, S.G.; Durham, S.D. Improved up-and-down designs for phase I trials. Stat Med. 2003, 22 (1), 69-82.
15. Babb, J.S.; Rogatko, A. Patient specific dosing in a cancer phase I clinical trial. Stat. Med. 2001, 20 (14), 2079-2090.
16. Couzin, J. Drug safety. withdrawal of Vioxx casts a shadow over COX-2 inhibitors. Science 2004, 306 (5695), 384-385.
17. Berenson, A. Jury calls Merck liable in death of man on Vioxx. NY Times 2005; Aug. 20.
18. Cheung, Y.K.; Chappell, R. Sequential designs for phase I clinical trials with late-onset toxicities. Biometrics 2000, 56 (4), 1177-1182.
19. Horng, S.; Grady, C. Misunderstanding in clinical research: distinguishing therapeutic misconception, therapeutic misestimation, and therapeutic optimism. IRB 2003, 25 (1), 11-16.
20. Daugherty, C.K. Informed consent, the cancer patient, and phase I clinical trials. Cancer Treat. Res. 2000, 102, 77-89.
21. Kodish, E.; Stocking, C.; Ratain, M.J.; Kohrman, A.; Siegler, M. Ethical issues in phase I oncology research: a comparison of investigators and institutional review board chairpersons. J. Clin. Oncol. 1992, 10 (11), 1810-1816.
22. Daugherty, C.; Ratain, M.J.; Grochowski, E.; Stocking, C.; Kodish, E.; Mick, R.; Siegler, M. Perceptions of cancer patients and their physicians involved in phase I trials. J. Clin. Oncol. 1995, 13 (5), 1062-1072.
23. Hutchison, C. Phase I trials in cancer patients: participants' perceptions. Eur. J. Cancer Care (Engl.) 1998, 7 (1), 15-22.
24. Schutta, K.M.; Burnett, C.B. Factors that influence a patient's decision to participate in a phase I cancer clinical trial. Oncol. Nurs. Forum 2000, 27 (9), 1435-1438.
25. Daugherty, C.K. Impact of therapeutic research on informed consent and the ethics of clinical trials: a medical oncology perspective. J. Clin. Oncol. 1999, 17 (5), 1601-1617.
26. Daugherty, C.K. Ethical issues in the development of new agents. Invest. New Drugs 1999, 17 (2), 145-153. [review]
27. Horng, S.; Emanuel, E.J.; Wilfond, B.; Rackoff, J.; Martz, K.; Grady, C. Descriptions of benefits and risks in consent forms for phase 1 oncology trials. N. Engl. J. Med. 2002, 347 (26), 2134-2140.
28. American Society of Clinical Oncology. Critical role of phase I clinical trials in cancer treatment. J. Clin. Oncol. 1997, 15 (2), 853-859. [review]
29. Miller, M. Phase I cancer trials. A collusion of misunderstanding. Hastings Cent. Rep. 2000, 30 (4), 34-43.
30. Kapo, J.; Casarett, D. Palliative care in phase 1 trials: an ethical obligation or undue inducement? J. Palliat. Med. 2002, 5 (5), 661-665.
31. Casarett, D.J.; Karlawish, J.H.; Henry, M.I.; Hirschman, K.B. Must patients with advanced cancer choose between a Phase I trial and hospice? Cancer 2002, 95 (7), 1601-1604.